Wnt signaling pathway

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

Retrieved on: 
Tuesday, November 14, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, Hope, Diabetic retinopathy, Retina, Omega, Patient, DME, Eye, Part, Series, Permeability, MD, Macular degeneration, Doctor of Philosophy, Physician, Wnt signaling pathway, Paratriathlon, Pharmaceutical industry

EyeBio will use the proceeds from the funding to accelerate the Company’s clinical development program and further build out its innovative retina pipeline.

Key Points: 
  • EyeBio will use the proceeds from the funding to accelerate the Company’s clinical development program and further build out its innovative retina pipeline.
  • “We’re excited to be a part of the Series A extension along with Bain Capital Life Sciences and Vertex Ventures HC.
  • “The expansion of our Series A round in the current fundraising environment speaks to our investors’ enthusiasm for what the EyeBio team is accomplishing.
  • “We hear constantly from retinal physicians about the need to drive better outcomes for their patients and the demand for novel approaches to treating serious retinal diseases.

This Week in Transportation News: 10 Stories You Need to See

Retrieved on: 
Friday, September 8, 2023
Database, Partnership, Vertical, Alice, Related, Carbon, Concept, PEM, Magic carpet, NASA, Air travel, Wnt signaling pathway, Tesla Model S, PR Newswire, Transport, News, Subject-matter expert, Geography, Airline, Mobile phone, Publishing

NEW YORK, Sept. 8, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the auto and transportation industries stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • Range Using NASA-Proven "Thrusters"
    An exciting new mode of personal airborne mobility, about the size of a Tesla Model S, has been revealed by Applied eVTOL Concepts.
  • The Epiphany™ Transporter evokes dreams of Aladdin's Magic Carpet, providing swift, door-to-door, transportation with VTOL (Vertical Take-Off and Landing) capability.
  • Subject Matter Experts: Access ProfNet , a database of industry experts to connect with as sources or for quotes in your articles.
  • Related Resources: Read and subscribe to our journalist- and blogger-focused blog, Beyond Bylines , for media news roundups, writing tips, upcoming events, and more.

EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema

Retrieved on: 
Wednesday, June 14, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Retina, DME, Eye, Clinical trial, Wnt signaling pathway, Research, Diabetic retinopathy, IVT, Acquisition, Permeability, Patient, Standard of care, Biology, Visual acuity, Safety, Pharmaceutical industry

Eyebiotech Limited (EyeBio) , a clinical-stage ophthalmology biotechnology company, today announced the dosing of the first participants in its Phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Key Points: 
  • Eyebiotech Limited (EyeBio) , a clinical-stage ophthalmology biotechnology company, today announced the dosing of the first participants in its Phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).
  • The AMARONE trial will evaluate the safety and preliminary efficacy of intravitreal (IVT) Restoret™ (EYE103) and is the first clinical trial from EyeBio’s diversified pipeline of multi-specific antibodies.
  • “Restoret has the potential to address a major unmet need in these diseases, namely excess fluid in the retina,” said Tony Adamis, M.D., Chief Scientific Officer of EyeBio.
  • “Initiation of the AMARONE trial marks an important milestone in our mission to address the urgent unmet need for individuals living with neovascular age-related macular degeneration and diabetic macular edema,” said Jonathan Prenner, M.D., Chief Medical Officer of EyeBio.

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

Retrieved on: 
Tuesday, May 30, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pancreatic cancer, American Journal of Clinical Oncology, Hepatology, Progression-free survival, Safety, Wnt signaling pathway, Rabin Medical Center, Cell, Cancer, Liver cancer, Journal, Patient, Pancreas, CANF, Kidwai Memorial Institute of Oncology, TASE, NYSE, Pharmaceutical industry

The abstract can be read here: LINK

Key Points: 
  • The abstract can be read here: LINK
    The pre-clinical study used advanced pancreatic carcinoma patient cells that were treated with Namodenoson as a stand-alone and in combination with gemcitabine, the leading chemotherapy used to treat pancreatic cancer.
  • A significant dose-dependent inhibition of pancreatic cancer cell growth was found when the cells were exposed to Namodenoson.
  • The study will be conducted by Dr. Salomon Stemmer, an oncology key opinion leader and Professor at the Institute of Oncology, Rabin Medical Center, Israel.
  • “These encouraging results in pancreatic cancer are very much in line with our findings for Namodenoson in advanced liver cancer clinical trials,” stated Can-Fite CEO Dr. Pnina Fishman.

Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors

Retrieved on: 
Tuesday, March 14, 2023
Disease, Gene, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Neoplasm, Attention deficit hyperactivity disorder predominantly inattentive, Clinical trial, Immunosuppression, Tumor microenvironment, Wnt signaling pathway, Cancer, Patient, Food, Therapy, Safety, Cholangiocarcinoma, FDA, Pharmaceutical industry, Vaccine, WNT, Wisdom

HARRISON, N.Y., March 14, 2023 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced today that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with its Phase 1-2 clinical trial of ST316 for the treatment of solid tumors.  Sapience expects to begin patient dosing in the Phase 1 dose escalation portion of the study in the first half of 2023 to evaluate the safety, clinical activity, pharmacokinetics and pharmacodynamics of ST316.

Key Points: 
  • β-catenin is the effector protein of the Wnt signaling pathway, one of the most important oncogenic pathways.
  • ST316 separates β-catenin's physiologic and oncogenic activities, enabling treatment of Wnt-driven tumors while keeping normal β-catenin function intact.
  • "FDA clearance of the ST316 IND is an exciting achievement for Sapience, representing the second therapeutic candidate we discovered to advance into clinical development," said Dr. Barry Kappel, CEO and President of Sapience.
  • The Phase 1 dose-escalation portion of the study is designed as a basket study to enroll patients with tumors likely to harbor abnormalities of the Wnt/β-catenin signaling pathway.

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Retrieved on: 
Monday, May 16, 2022
Bowel obstruction, Senior, Anti-inflammatory, Colon, Wall, Inflammation, Epithelium, Degenerative disease, UC, Disease, Hyperplasia, Soft tissue injury, U.S. Securities and Exchange Commission, Retina, Ulcerative colitis, Patient, Biology, Homeostasis, Infection, Hearing loss, Coronavirus, Wnt signaling pathway, Liver, Cochlea, COVID-19, Colitis, Cell, LRP6, Kidney, Research, Inflammatory bowel disease, SAN, Hepatology, DSS, Probability, Lists of disasters, Forward-looking statement, Central nervous system, Technology, Regeneration, Lists of diseases, Lung, Therapy, Security (finance), Eye, Annual report, Hepatitis, ECCO, Tissue, GLOBE, Pharmaceutical industry, FZD5, WNT

The results seen with one of Surrozens proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease.

Key Points: 
  • The results seen with one of Surrozens proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease.
  • SZN-1326 demonstrated the most rapid and robust repair of the injured colon epithelium without affecting normal epithelium and without causing hyperplasia.
  • In the intestine, Wnt signaling plays an important role in maintaining integrity of the epithelium as part of tissue homeostasis and during injury repair.
  • Surrozen designed an antibody-based platform that generates potent Wnt mimetics, which specifically target select Fzd receptors and co-receptors.

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022
Molecule, Boston University School of Medicine, S1P, Inflammation, Company, KOL, Pharmacology, Toxicology, Numerical, Nasdaq, Doctor of Philosophy, Patient, Teaching hospital, Therapy, Pharmacokinetics, Minocycline, Atopic dermatitis, Boston University School of Public Health, Trial of the century, Journey, AD, JAK, Mouse, IND, Fibrosis, Wnt signaling pathway, Finance, Biomarker, Rheumatoid arthritis, Vitiligo, Regeneration, Animal, SEC, LLC, Dexamethasone, GLOBE, BET, Itch, Sumathi Best Television Current Reporting Award, MD, Achievement, WNT, Pharmaceutical industry

BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the quarter ended March31, 2022 and provided a business update.
  • VYNE made significant progress in the first quarter of 2022 with our pipeline of novel programs for immuno-inflammatory conditions, said David Domzalski, Chief Executive Officer of VYNE.
  • Looking ahead, we plan to report Phase 2a safety and efficacy results for FMX114 by the end of the second quarter.
  • FMX114 is currently being evaluated in a Phase 2a study with topline results expected by the end of the second quarter.

Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906’s Immunomodulatory Mechanisms in Combination with Immune Checkpoint or CAR T Therapy

Retrieved on: 
Friday, April 8, 2022
Memorial Sloan Kettering Cancer Center, Method, CGMP, Quality control, Therapy, Systems biology, Immunotherapy, Sorafenib, Liver, Tumor microenvironment, Biotechnology, COX2, Hepatocellular carcinoma, NF, Cancer, WNT, Food, Inflammation, Wnt signaling pathway, Queen Mary's Hospital, Orphan drug, Signal transduction, Gastrointestinal tract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCC, Yale University, IL-6, Taipei Medical University, FDA, Pancreatic cancer, Patient, M1, Pharmaceutical industry

NEW HAVEN, Conn and NEW YORK and SHANGHAI, April 08, 2022 (GLOBE NEWSWIRE) -- Yiviva and Yale scientists will present new data from Yiviva’s oncology portfolio at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans on April 8-13, 2022.

Key Points: 
  • YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications.
  • YIV-906 has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers.
  • Yiviva is a clinical stage, platform biotechnology company developing multi-targeted, systems biology therapeutics, focused on cancer and inflammatory diseases.
  • The company was launched with Yale University as a co-founder and co-founders include Yung Chi Cheng, Ph.D. For further information, please visit https://yiviva.com .

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Retrieved on: 
Monday, January 10, 2022
Parker, Idiopathic pulmonary fibrosis, Tissue, SAN, Lists of disasters, Growth, AMD, Central nervous system, Disease, Retinopathy, FZD4, Hearing loss, Hepatitis, Eye, Security (finance), Coronavirus, Goal, Liver, Fibrosis, Institute of Liver and Biliary Sciences, Chronic obstructive pulmonary disease, IND, Lists of diseases, U.S. Securities and Exchange Commission, Acceleration, Duane syndrome, Regeneration, Lung, Inflammatory bowel disease, Alcoholic hepatitis, Cochlea, Diabetic retinopathy, Probability, Forward-looking statement, IPF, Liver injury, Retina, Research, Ophthalmology, Soft tissue injury, Degenerative disease, Nasdaq, Technology, Kidney, Homeostasis, Wnt signaling pathway, COVID-19, Infection, Therapy, GLOBE, Inflammation, Maintenance, COPD, Pharmaceutical industry, Vaccine, Medical imaging, WNT

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced key development goals and acceleration of its research pipeline as the company transitions to a clinical-stage biotechnology company.

Key Points: 
  • 2022 promises to be a transformational year for Surrozen, as it marks our planned entry into the clinic for two novel therapeutic candidates, said Craig Parker, President and Chief Executive Officer of Surrozen.
  • Furthermore, we have expanded to a third therapeutic area in ophthalmology with the recent nomination of lead candidate SZN-413.
  • Parker continued, Our discovery programs continue to identify new areas where our Wnt platform technologies could have therapeutic impact, including lacrimal gland and lung.
  • SZN-1326 is the first development candidate designed using Surrozens SWAPTM technology and targets the Wnt signaling pathway in the intestinal epithelium.

FogPharma Expands Executive Leadership Team

Retrieved on: 
Monday, November 22, 2021
Biotechnology, General Health, Pharmaceutical, Health, Patient, Harvard University, Technology, Disease, Merck, Wnt signaling pathway, Leadership, AstraZeneca, Boston University, Massachusetts General Hospital, Pharmacovigilance, Informatics, Research, Tsinghua University, GlaxoSmithKline, Hospital, Biomedical engineering, Internal medicine, Drug discovery, Drug development, Harvard Medical School, Computational biology, Georgetown University, Massachusetts, Management, Fine chemical, Pharmaceutical industry

“Lihua and Keith are accomplished drug development executives and we are excited to welcome them to our growing leadership team,” said Gregory Verdine, Ph.D., founder and chief executive officer of FogPharma. “It has been a fantastic year of progress at FogPharma -- we closed a $107 million Series C financing round, continued to build out our multiplexed and machine learning-enabled drug discovery engine and further advanced our lead cancer programs, including our first-and-only-in-class direct β-catenin inhibitor. Keith and Lihua will be critical to our future success as we continue to scale.”

Key Points: 
  • Lihua and Keith are accomplished drug development executives and we are excited to welcome them to our growing leadership team, said Gregory Verdine, Ph.D., founder and chief executive officer of FogPharma.
  • Dr. Yu brings over 20 years of experience and leadership in data sciences across computational biology, cancer genomics, research informatics, clinical genomics, real world data and evidence.
  • Dr. Orford joins FogPharma from Calithera Biosciences, where as chief medical officer, he led the companys clinical development, clinical operations, biometrics, pharmacovigilance and medical affairs functions.
  • FogPharma is headquartered in Cambridge, Mass., and has raised more than $180 million to date from leading life sciences investors.